Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.

Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP.

Leuk Lymphoma. 2013 Sep;54(9):1915-20. doi: 10.3109/10428194.2013.763397. Epub 2013 Jan 30.

2.

A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.

Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS.

Biol Blood Marrow Transplant. 2011 Jul;17(7):987-94. doi: 10.1016/j.bbmt.2010.10.016. Epub 2010 Oct 20.

3.

Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.

Suzuki T, Yamauchi T, Ando K, Nagai T, Kakihana K, Miyata Y, Uchida T, Tabata Y, Ogura M.

Jpn J Clin Oncol. 2013 Dec;43(12):1177-83. doi: 10.1093/jjco/hyt155. Epub 2013 Oct 14.

4.

Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.

Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P.

Cancer. 2011 Apr 1;117(7):1490-7. doi: 10.1002/cncr.25603. Epub 2010 Nov 8.

5.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.

Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC.

Leuk Lymphoma. 2009 Mar;50(3):349-56. doi: 10.1080/10428190902730227.

6.

Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.

Jacoby MA, Martin MG, Uy GL, Westervelt P, Dipersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN.

Am J Hematol. 2014 May;89(5):487-92. doi: 10.1002/ajh.23663. Epub 2014 Mar 3.

7.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
8.

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S.

Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9.

9.

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, Luchtman-Jones L, Bomgaars L, Gaynon P, Goldman S, Ritchey K, Arceci R, Altman A, Stine K, Steinherz L, Steinherz P.

J Clin Oncol. 2009 Sep 10;27(26):4392-7. doi: 10.1200/JCO.2008.18.8706. Epub 2009 Aug 3.

10.

Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.

Zoellner AK, Fritsch S, Prevalsek D, Engel N, Hubmann M, Reibke R, Rieger CT, Hellmuth JC, Haas M, Mumm F, Herold T, Ledderose G, Hiddemann W, Dreyling M, Hausmann A, Tischer J.

Bone Marrow Transplant. 2015 May;50(5):679-84. doi: 10.1038/bmt.2014.328. Epub 2015 Feb 2.

PMID:
25642765
11.

The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.

McGregor BA, Brown AW, Osswald MB, Savona MR.

Am J Hematol. 2009 Apr;84(4):228-30. doi: 10.1002/ajh.21365. Review.

12.

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.

Simko SJ, Tran HD, Jones J, Bilgi M, Beaupin LK, Coulter D, Garrington T, McCavit TL, Moore C, Rivera-Ortegón F, Shaffer L, Stork L, Turcotte L, Welsh EC, Hicks MJ, McClain KL, Allen CE.

Pediatr Blood Cancer. 2014 Mar;61(3):479-87. doi: 10.1002/pbc.24772. Epub 2013 Sep 18.

13.

Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.

Barba P, Sampol A, Calbacho M, Gonzalez J, Serrano J, Martínez-Sánchez P, Fernández P, García-Boyero R, Bueno J, Ribera JM.

Am J Hematol. 2012 Jun;87(6):631-4. doi: 10.1002/ajh.23167. Epub 2012 Mar 19.

14.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.

Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.

PMID:
25042202
15.

Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.

O'Connor D, Sibson K, Caswell M, Connor P, Cummins M, Mitchell C, Motwani J, Taj M, Vora A, Wynn R, Kearns PR.

Br J Haematol. 2011 Aug;154(4):482-5. doi: 10.1111/j.1365-2141.2011.08752.x. Epub 2011 Jun 21.

PMID:
21689087
16.

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE.

Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18.

17.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

PMID:
25925619
18.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM.

J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5.

19.

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.

Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H; CLASSIC II Investigators.

Leuk Lymphoma. 2012 Mar;53(3):435-40. doi: 10.3109/10428194.2011.616960. Epub 2011 Oct 24.

PMID:
21877883
20.

[Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].

Suo P, Zhang LP, Wu J, Lu AD, Wang B, Zuo YX, Cheng YF, Liu GL.

Zhongguo Dang Dai Er Ke Za Zhi. 2013 Jun;15(6):444-7. Chinese.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk